We are pleased to have served as lead manager for TScan Therapeutics' Upsized $150.1 million follow-on offering. Learn more about us and all of our transactions at https://lifescicapital.com
LifeSci Capital LLC’s Post
More Relevant Posts
-
#Slack DMs can make it hard to track requests and measure workload impact of your #ITHelpdesk. Hear how Cohere, Xilio Therapeutics and Foqal took back control 4/17 webinar https://hubs.li/Q02pyTc90
To view or add a comment, sign in
-
-
#Slack DMs can make it hard to track requests and measure workload impact of your #ITHelpdesk. Hear how Cohere, Xilio Therapeutics and Foqal took back control in 4/17 webinar https://hubs.ly/Q02pyQ0V0
To view or add a comment, sign in
-
-
The interim report for the third quarter is now available! Stayble Therapeutics has published its interim report for the third quarter of 2023. Comment from our CEO, Andreas Gerward: “We at Stayble aim for every shareholder to clearly understand the differences between our two different indications. From now on, we will carefully analyze the data from the phase 2b study. We plan to update the market with more detailed information on all the data and explain why our belief in the potential of the herniated disc project still remains.” Explore the full report by following the link: https://lnkd.in/emAFbjw5
To view or add a comment, sign in
-
-
The way to win at healthcare investing is knowing the best companies BEFORE they are public. Thanks, LifeSci, for blazing the trail.
We are pleased to have served as sole and exclusive placement agent for Vyne Therapeutics' $88 million private placement. Learn more about us and all of our transactions at https://lifescicapital.com
To view or add a comment, sign in
-
-
The patient is at the heart of what we do at Cyclo Therapeutics. Learn more about our approach to patient-focused drug development here: https://bit.ly/3OMEDzh #NiemannPick #NPC1 #AlzheimersDisease
To view or add a comment, sign in
-
-
SPAC Feed: Coeptis Therapeutics becomes clinical-stage company following … – The Business Journals - https://lnkd.in/e6vefqq6 Coeptis Therapeutics becomes clinical-stage company following … The Business Journals Source: Coeptis Therapeutics becomes clinical-stage company following … – The Business… #SPACs #SPACNews #SPAC #IPO #markets #news #capitalmarkets #trends #goingpublic
To view or add a comment, sign in
-
On Tuesday we announced our first quarter 2024 financial results. On the earnings call, CEO Todd Davis, and members of the Ligand senior management team, highlighted our positive momentum during the first quarter, the significant progress of our commercial and development stage portfolio including our recent #royaltyfinancing agreement with Agenus and the launch of Pelthos Therapeutics, and the key growth drivers for the remainder of the year. View our earnings release here: https://bit.ly/4acV1D5
To view or add a comment, sign in
-
-
𝗖𝗼𝗻𝘁𝗶𝗻𝗲𝘂𝗺 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝗳𝗶𝗹𝗲𝘀 𝗳𝗼𝗿 𝗜𝗣𝗢 𝘄𝗶𝘁𝗵 𝗠𝗦 𝗱𝗿𝘂𝗴 𝗶𝗻 𝗣𝗵𝗮𝘀𝗲 𝗜𝗜 Clinical-stage biotech Contineum Therapeutics, which until recently went by the name Pipeline Therapeutics, on Friday revealed plans to go public under the Nasdaq ticker $CTNM. The biotech’s drug PIPE-307 is being studied in patients with relapsing-remitting multiple sclerosis, or RRMS. It’s in Phase II, fitting the profile of IPO that investors have been seeking after two dismal years of new entrants to the market. Carmine Stengone. https://lnkd.in/e2Y_q8wS
Contineum Therapeutics files for IPO with MS drug in PhII
https://endpts.com
To view or add a comment, sign in
-
If your team is using #Slack for internal IT Helpdesk Support and that experience could be improved, I have two suggestions: 1) Sign up for this Foqal webinar; and 2) contact me!!!
👉 Learn how Xilio Therapeutics runs their IT Support HelpDesk in Slack in this upcoming webinar. https://hubs.li/Q02ryVxK0 Webinar: Ditch the Slack DM Chaos: Regain Control of IT Support Join leaders from Cohere, Xilio Therapeutics, and Foqal who will share their real-world experiences in building successful Slack-powered IT help desks. April 17th @10am
To view or add a comment, sign in
-
-
One small step to share our dreams --- we are now in business K2B Therapeutics A LabCentral Company [Introduction] K2B Therapeutics is a pre-clinical stage therapeutic development startup, commercializing a novel science from the Korea Institute of Science and Technology (KIST), that enables targeted delivery of siRNA to extrahepatic cells using a first-in-kind protein-RNA conjugate. 1. Targeted delivery of siRNA to extrahepatic cells (like tumor) --- aka “something Alnylam could not do yet” 2. Potent “one-two punch” therapeutic effects to accelerate immuno-oncological response --- aka “something Gilead should have known” 3. Robust “modular drug design” platform to efficiently develop multiple candidates --- aka “something Lilly would love to be associated with” [Strategic opportunity] Despite recent successes in mRNA vaccines and a handful of siRNA-based drugs in the commercial market, the RNAi therapeutics sector is limited to the mechanism of “systemic delivery via gravity pull,” and has yet to discover safe and efficient ways to deliver this potentially potent therapeutic modality to more urgent targets like tumor cells. [Core platform technology] By conjugating a specific gene silencing siRNA to a protein that binds to tumor specific receptors, K2B’s PRC platform provides an efficient and robust mechanism for generating many therapeutic candidates in the oncology sector. [Lead candidate in immuno-oncology] K2B’s first drug candidate, KB100-series, is being developed as a best-in-class drug to inhibit CD47, a well-known immune check point often called “don’t eat me” signals. While other CD47 players are struggling to sufficiently block over-expressed CD47 through mechanisms like antibody, K2B knocks down cancer’s ability to express CD47 from its root by sending gene-silencing siRNA to inside the tumor cells. Recent in vivo studies show our first candidate KB101 is successful in inhibiting tumor growth via a substantial increase in the recruitment of proinflammatory macrophage as well as a significant augmentation of T-cell infiltration. [Expansion of pipeline] From the design, development, and optimization of KB100 series, our team has gained valuable knowledge and insights about the nature of this protein-RNA conjugate technology. The PRC platform enables a completely new drug discovery principle called modular drug design, and K2B is currently developing several different oncology leads targeting some “undruggable” oncogenes.
We cannot hide it any longer - coming out with our vision! From KIST to Boston = K2B Therapeutics.
To view or add a comment, sign in
-